Lv2
110 积分 2024-05-08 加入
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
12天前
已完结
Cancer incidence and mortality in China, 2022
1个月前
已完结
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
1个月前
已完结
ATM and p53 in aging and cancer: a double-edged sword in genomic integrity
3个月前
已完结
Mantle-Cell Lymphoma
1年前
已完结
[The guideline of the diagnosis and treatment of mantle cell lymphoma in China (2022)]
1年前
已完结
Global patterns of non‐Hodgkin lymphoma in 2020
1年前
已完结
Chronic lymphocytic leukaemia
1年前
已完结
Expert consensus on the management of chronic lymphocytic leukaemia in Asia
1年前
已完结
Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma
1年前
已关闭
皖公网安备34019202002308
